Associated Papers
Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms.
Morishita S et al.
International Journal of Molecular Sciences, 2023
37629188 (PubMed )
Supplement: ijms-24-13008-s001.zip › ijms-2555672-supplementary.pdf
Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice.
Minakawa K et al.
Journal of Hematology & Oncology, 2021
33785036 (PubMed )
Supplement: 13045_2021_1064_MOESM7_ESM.pdf
Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.
Vu HA et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2019
Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis.
Christopeit M et al.
Bone Marrow Transplantation, 2016
Low neutrophil alkaline phosphatase score is a new aspect of calreticulin-mutated myeloproliferative neoplasms.
Kondo T et al.
Springerplus, 2016
The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.
Lin Y et al.
American Journal of Clinical Pathology, 2015
Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring.
Chi J et al.
Annals of Hematology, 2015
Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.
Park SH et al.
Annals of Laboratory Medicine, 2015
Select a paper to view details